Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 29

Sort by

Sort Order Select

Journal Articles

Two-year follow-up of lisocabtagene maraleucel in relapsed or refractory large B-cell lymphoma in TRANSCEND NHL 001

Jeremy S. Abramson, M. Lia Palomba, Leo I. Gordon, Matthew Lunning, Michael Wang, Jon Arnason, Enkhtsetseg Purev, David G. Maloney, Charalambos Andreadis, Alison Sehgal, Scott R. Solomon, Nilanjan Ghosh, Christine Dehner, Yeonhee Kim, Ken Ogasawara, Ana Kostic, Tanya Siddiqi

Blood (2024) 143 (5): 404–416.

https://doi.org/10.1182/blood.2023020854

Published: 2024

Includes: Supplemental data

Journal Articles

Phase 2 clinical trial evaluating abatacept in patients with steroid-refractory chronic graft-versus-host disease

Blood (2023) 141 (24): 2932–2943.

https://doi.org/10.1182/blood.2022019107

Published: 2023

Includes: Supplemental data

Journal Articles

Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the phase 3 TRANSFORM study

Jeremy S. Abramson, Scott R. Solomon, Jon Arnason, Patrick B. Johnston, Bertram Glass, Veronika Bachanova, Sami Ibrahimi, Stephan Mielke, Pim Mutsaers, Francisco Hernandez-Ilizaliturri, Koji Izutsu, Franck Morschhauser, Matthew Lunning, Alessandro Crotta, Sandrine Montheard, Alessandro Previtali, Ken Ogasawara, Manali Kamdar

Blood (2023) 141 (14): 1675–1684.

https://doi.org/10.1182/blood.2022018730

Published: 2023

Includes: Supplemental data

Journal Articles

Phase 1 TRANSCEND CLL 004 study of lisocabtagene maraleucel in patients with relapsed/refractory CLL or SLL

Tanya Siddiqi, Jacob D. Soumerai, Kathleen A. Dorritie, Deborah M. Stephens, Peter A. Riedell, Jon Arnason, Thomas J. Kipps, Heidi H. Gillenwater, Lucy Gong, Lin Yang, Ken Ogasawara, Jerill Thorpe, William G. Wierda

Blood (2022) 139 (12): 1794–1806.

https://doi.org/10.1182/blood.2021011895

Published: 2022

Includes: Supplemental data

Journal Articles

Contribution of clonal hematopoiesis to adult-onset hemophagocytic lymphohistiocytosis

Blood (2020) 136 (26): 3051–3055.

https://doi.org/10.1182/blood.2020008206

Published: 2020

Includes: Supplemental data

Journal Articles

Phase 1 clinical trial evaluating abatacept in patients with steroid-refractory chronic graft-versus-host disease

Blood (2018) 131 (25): 2836–2845.

https://doi.org/10.1182/blood-2017-05-780239

Published: 2018

Includes: Supplemental data

Journal Articles

MUC1-mediated induction of myeloid-derived suppressor cells in patients with acute myeloid leukemia

Blood (2017) 129 (13): 1791–1801.

https://doi.org/10.1182/blood-2016-07-730614

Published: 2017

Includes: Supplemental data

Journal Articles

Transcend NHL 001: Immunotherapy with the CD19-Directed CAR T-Cell Product JCAR017 Results in High Complete Response Rates in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Jeremy S. Abramson, MD, Lia Palomba, MD, Leo I Gordon, MD, Matthew Lunning, DO, Jon Arnason, MD, Andres Forero-Torres, MD, Tina M. Albertson, MD PhD, Victoria Shaw Exton, Claire Sutherland, PhD, Benhuai Xie, PhD, Susan Snodgrass, MD, Tanya Siddiqi, MD

Blood (2016) 128 (22): 4192.

https://doi.org/10.1182/blood.V128.22.4192.4192

Published: 2016

Journal Articles

MUC1-C Inhibition Leads to Decrease in PD-L1 Levels Via up-Regulation of Micro RNAs

Blood (2016) 128 (22): 2871.

https://doi.org/10.1182/blood.V128.22.2871.2871

Published: 2016

Journal Articles

Phase I Clinical Trial Evaluating Abatacept in Patient with Steroid-Refractory Chronic Graft Versus Host Disease

Blood (2016) 128 (22): 387.

https://doi.org/10.1182/blood.V128.22.387.387

Published: 2016

Journal Articles

Decitabine Priming Enhances Mucin 1 Inhibition Mediated Disruption of Redox Homeostasis in Cutaneous T-Cell Lymphoma

Salvia Jain, MD, Abigail J. Washington, BA, Rebecca Karp Leaf, MD, Parul Bhargava, MD, Rachael Clark, MD PhD, Thomas S. Kupper, MD, Dina Stroopinsky, PhD, Athalia Rachel Pyzer, MD, Leandra Cole, BA, Myrna R. Nahas, MD, Arie Apel, MD, Jacalyn Rosenblatt, MD, Jon Arnason, MD, Donald Kufe, MD, David E. Avigan, MD

Blood (2016) 128 (22): 4175.

https://doi.org/10.1182/blood.V128.22.4175.4175

Published: 2016

Journal Articles

Phase 1 Study of REGN1979, an Anti-CD20 x Anti-CD3 Bispecific Monoclonal Antibody, in Patients with CD20+ B-Cell Malignancies Previously Treated with CD20-Directed Antibody Therapy

Rajat Bannerji, MD PhD, Jennifer R. Brown, MD PhD, Ranjana H Advani, MD, Jon Arnason, MD, Susan M. O'Brien, MD, John N. Allan, MD, Julio C. Chavez, MD, Jeffrey A. Barnes, MD PhD, Robin Joyce, MD, Stephen Ansell, MD PhD, Max S Topp, MD, Lieve Adriaens, PharmD, Melanie Ufkin, PhD, Ana Kostic, PhD, Anne Paccaly, PharmD, PhD, Bo Gao, PhD, Pamela A. Trail, PhD, Israel Lowy, MD PhD, Carrie Brownstein, MD

Blood (2016) 128 (22): 621.

https://doi.org/10.1182/blood.V128.22.621.621

Published: 2016

Journal Articles

TGR-1202 in Combination with Ibrutinib in Patients with Relapsed or Refractory CLL or MCL: Preliminary Results of a Multicenter Phase I/Ib Study

Matthew S. Davids, Haesook T. Kim, PhD, Alyssa Nicotra, BA, Alexandra Savell, BS, Karen Francoeur, RN, Jeffrey Hellman, PA-C, Hari P. Miskin, MS, Peter Sportelli, Asad Bashey, MD PhD, Laura Stampleman, MD, Jens Rueter, MD, Adam Boruchov, MD, Jon Arnason, MD, Caron A. Jacobson, MD, David C. Fisher, MD, Jennifer R. Brown

Blood (2016) 128 (22): 641.

https://doi.org/10.1182/blood.V128.22.641.641

Published: 2016

Journal Articles

A Novel Dendritic Cell-Derived Vaccine in Multiple Myeloma

Rebecca Karp Leaf, MD, Dina Stroopinsky, PhD, Athalia Rachel Pyzer, MD, Ada M. Kruisbeek, PhD, Sandra Van Wetering, PhD, Abigail J. Washington, BA, Leandra Cole, BA, Myrna R. Nahas, MD, Salvia Jain, MD, Arie Apel, MD, Jon Arnason, MD, Ayad Hamdan, MD, Jacalyn Rosenblatt, MD, David E. Avigan, MD

Blood (2016) 128 (22): 4484.

https://doi.org/10.1182/blood.V128.22.4484.4484

Published: 2016

Journal Articles

Acute Myeloid Leukemia Cells Export c-Myc in Extracellular Vesicles Driving a Proliferation of Immune-Suppressive Myeloid-Derived Suppressor Cells

Athalia Rachel Pyzer, MD, Dina Stroopinsky, PhD, Hasan Rajabi, PhD, Abigail J. Washington, BA, Leandra Cole, BA, Salvia Jain, MD, Ashujit Tagde, PhD BPharm, Arie Apel, MD, Malgorzata McMasters, MD, James D. Levine, MD, Robin Joyce, MD, Jon Arnason, MD, Poorvi Somaiya, Rebecca Karp Leaf, MD, Myrna R. Nahas, MD, Donald Küfe, MD, Jacalyn Rosenblatt, MD, David E. Avigan, MD

Blood (2016) 128 (22): 703.

https://doi.org/10.1182/blood.V128.22.703.703

Published: 2016

Journal Articles

MUC1 Inhibition Overcomes Chemotherapy Resistance in Acute Myeloid Leukemia

Myrna Rita Nahas, MD, Dina Stroopinsky, PhD, Hasan Rajabi, PhD, Ashujit Tagde, PhD, Athalia Rachel Pyzer, MD, Salvia Jain, MD, Maxwell Douglas Coll, Michal Bar-Natan, MD, Rebecca Karp, MD, Katarina Luptakova, MD, Kristen Anna Palmer, Poorvi Somaiya, Jon Arnason, MD, Malgorzata McMasters, MD, Robin Joyce, MD, James D. Levine, MD, Donald Kufe, MD, David Avigan, MD, Jacalyn Rosenblatt

Blood (2015) 126 (23): 2473.

https://doi.org/10.1182/blood.V126.23.2473.2473

Published: 2015

Journal Articles

Mucin 1 is a potential therapeutic target in cutaneous T-cell lymphoma

Salvia Jain, Dina Stroopinsky, Li Yin, Jacalyn Rosenblatt, Maroof Alam, Parul Bhargava, Rachael A. Clark, Thomas S. Kupper, Kristen Palmer, Maxwell D. Coll, Hasan Rajabi, Athalia Pyzer, Michal Bar-Natan, Katarina Luptakova, Jon Arnason, Robin Joyce, Donald Kufe, David Avigan

Blood (2015) 126 (3): 354–362.

https://doi.org/10.1182/blood-2015-02-628149

Published: 2015

Includes: Supplemental data

Journal Articles

Mucin-1 (MUC1) Oncoprotein in Multiple Myeloma Cells Inhibits the Th1 Responses By Down Regulating the Expression of Mir-200c and up-Regulating the PDL1 Expression

Hasan Rajabi, PhD, Maxwell Douglas Coll, Jacalyn Rosenblatt, MD, Li Yin, PhD, Dina Stroopinsky, PhD, Katarina Luptakova, MD, Baldev Vasir, PhD, Athalia Rachel Pyzer, MD, Kristen Palmer, Michal Bar-Natan, MD, Salvia Jain, MD, Poorvi Somaiya, MSc, Jon Arnason, MD, Donald Kufe, MD, David Avigan, MD

Blood (2014) 124 (21): 2072.

https://doi.org/10.1182/blood.V124.21.2072.2072

Published: 2014

Journal Articles

Inhibition of Phosphorylation of ERK in CLL Cells Pre-Treatment Correlates Best with Response to Dasatinib, Fludarabine, and Rituximab for Patients with Relapsed CLL

Philip C. Amrein, MD, Xin Kai, Yasuyuki Iuchi, Jon Arnason, MD, Jennifer R. Brown, MD PhD, Karen K. Ballen, MD, Eyal C. Attar, MD, Amir T Fathi, Ephraim P. Hochberg, HyukJoo Hwang, Shiv Pillai

Blood (2014) 124 (21): 3636.

https://doi.org/10.1182/blood.V124.21.3636.3636

Published: 2014

Journal Articles

Bone Marrow Stroma Protects Myeloma Cells from Cytotoxic Damage Via Induction of the Oncoprotein MUC1

Michal Bar-Natan, MD, Katarina Luptakova, MD, Maxwell Douglas Coll, Dina Stroopinsky, PhD, Hasan Rajabi, PhD, Athalia Rachel Pyzer, MD, Kristen A Palmer, Michaela R. Reagan, PhD, Poorvi Somaiya, MSc, Salvia Jain, MD, Jon Arnason, MD, Irene M. Ghobrial, MD, Jacalyn Rosenblatt, MD, Kenneth C. Anderson, MD, Donald Kufe, MD, David Avigan, MD

Blood (2014) 124 (21): 3378.

https://doi.org/10.1182/blood.V124.21.3378.3378

Published: 2014

NARROW

Two-year follow-up of lisocabtagene maraleucel in relapsed or refractory large B-cell lymphoma in TRANSCEND NHL 001

Phase 2 clinical trial evaluating abatacept in patients with steroid-refractory chronic graft-versus-host disease

Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the phase 3 TRANSFORM study

Phase 1 TRANSCEND CLL 004 study of lisocabtagene maraleucel in patients with relapsed/refractory CLL or SLL

Contribution of clonal hematopoiesis to adult-onset hemophagocytic lymphohistiocytosis

Phase 1 clinical trial evaluating abatacept in patients with steroid-refractory chronic graft-versus-host disease

MUC1-mediated induction of myeloid-derived suppressor cells in patients with acute myeloid leukemia

Transcend NHL 001: Immunotherapy with the CD19-Directed CAR T-Cell Product JCAR017 Results in High Complete Response Rates in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

MUC1-C Inhibition Leads to Decrease in PD-L1 Levels Via up-Regulation of Micro RNAs

Phase I Clinical Trial Evaluating Abatacept in Patient with Steroid-Refractory Chronic Graft Versus Host Disease

Decitabine Priming Enhances Mucin 1 Inhibition Mediated Disruption of Redox Homeostasis in Cutaneous T-Cell Lymphoma

Phase 1 Study of REGN1979, an Anti-CD20 x Anti-CD3 Bispecific Monoclonal Antibody, in Patients with CD20+ B-Cell Malignancies Previously Treated with CD20-Directed Antibody Therapy

TGR-1202 in Combination with Ibrutinib in Patients with Relapsed or Refractory CLL or MCL: Preliminary Results of a Multicenter Phase I/Ib Study

A Novel Dendritic Cell-Derived Vaccine in Multiple Myeloma

Acute Myeloid Leukemia Cells Export c-Myc in Extracellular Vesicles Driving a Proliferation of Immune-Suppressive Myeloid-Derived Suppressor Cells

MUC1 Inhibition Overcomes Chemotherapy Resistance in Acute Myeloid Leukemia

Mucin 1 is a potential therapeutic target in cutaneous T-cell lymphoma

Mucin-1 (MUC1) Oncoprotein in Multiple Myeloma Cells Inhibits the Th1 Responses By Down Regulating the Expression of Mir-200c and up-Regulating the PDL1 Expression

Inhibition of Phosphorylation of ERK in CLL Cells Pre-Treatment Correlates Best with Response to Dasatinib, Fludarabine, and Rituximab for Patients with Relapsed CLL

Bone Marrow Stroma Protects Myeloma Cells from Cytotoxic Damage Via Induction of the Oncoprotein MUC1

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only